（来源：劳动午报） 现场，院校、东城区与北京国有资本运营管理有限公司签约发布目标规模40亿元的"协和创新港"成果转 化基金，通用健康、华润医药、国药集团、中发展集团、联影集团、海尔集团、数坤科技、中欧医药健 康产业同学会、东城国资公司等9家"协和创新港"合作伙伴意向签约，并向"协和创新港"首席科学家颁 发聘书，向药物所、阜外医院等20余家首批入港项目及平台单位授牌。 据了解，"协和创新港"聚焦创新药物、新型疫苗、高端医疗器械、人工智能医疗等重点领域，构建"源 头创新-临床验证-成果转化-产业落地"的全链条闭环生态体系，形成"研发在院校、转化在东城、辐射京 津冀、带动全中国"的特色发展格局。该项目将分三阶段推进，起步区已完成改造并投入使用，计划到 2030年累计转化一批重大创新项目，培育数十家"协和系"高新技术企业，形成生物医药产业集群。东城 区将为项目提供空间载体、政策资源等全方位支持，双方将通过共建转化平台、共育专业人才，合力打 造医药健康创新策源地。 本报讯（记者 边磊） 近日，由中国医学科学院北京协和医学院（以下简称"院校"）与东城区委、东城 区人民政府主办的"协和创新港"项目启动会举行。会上，院校与东 ...

Core Viewpoint - Shanghai United Imaging Healthcare Co., Ltd. (United Imaging) has rapidly developed into a leading player in the high-end medical equipment sector, achieving a market value exceeding 100 billion yuan within just 15 years through a commitment to independent research and development and a comprehensive global strategy [6][7][8]. Group 1: Company Overview - United Imaging has established a comprehensive industrial matrix covering medical imaging, radiotherapy products, life science instruments, medical robots, smart wearable devices, and medical chips, achieving full-chain coverage from core technology to key components [6][8]. - The company has products installed in over 2,700 tertiary hospitals across China and has expanded its presence to more than 90 countries and regions, including the United States, Germany, France, India, and South Korea [6][11]. Group 2: Development Strategy - The company adheres to three core principles: full-line independent research and development, mastery of all core technologies, and alignment with international top standards, which have guided its development for over a decade [8][9]. - United Imaging has launched over 260 products, including advanced systems like the 5.0T whole-body MRI and the first integrated CT linear accelerator, setting multiple industry benchmarks [10]. Group 3: Global Expansion - United Imaging has adopted a "high-profile" global strategy, focusing on high-end self-researched innovative equipment to penetrate key markets and establish brand recognition in developed countries [12][13]. - The company has successfully entered the U.S. market, with over 400 units installed across more than 70% of state-level administrative regions, including over 150 PET/CT devices [13]. Group 4: Future Goals - The company aims to leverage national policy support to enhance its role as a "chain master" in the high-end medical equipment industry, focusing on innovation and integration of technology, industry, finance, and talent [15][16]. - United Imaging plans to build a multi-layered, international talent pool by 2030 and continue to deepen its international strategy, targeting Southeast Asia, Europe, India, and the U.S. for market expansion [17][18].

Core Insights - The article highlights the emergence of Chinese high-end medical equipment manufacturers, particularly United Imaging, as key players in the global market, showcasing their advanced technologies and products [1][2]. Group 1: Company Overview - United Imaging has developed several world-first medical devices, including a 2-meter PET-CT and a 5.0T full-body MRI, demonstrating its growth and the evolution of China's high-end medical equipment industry [1]. - The company has transitioned from being a mere assembler to a leader in the high-end imaging equipment market, previously dominated by international giants like GE, Philips, and Siemens [1]. Group 2: Technological Innovation - United Imaging's success is attributed to its commitment to mastering core technologies, guided by its principle of "three musts": comprehensive coverage, independent research and development, and alignment with international standards [2]. - The company has established over 40 regional headquarters and subsidiaries globally, focusing on localizing its research, production, and marketing efforts to enhance its global presence [2]. Group 3: Industry Impact - Under China's "14th Five-Year Plan," United Imaging is positioned as a leading enterprise that will drive significant growth in the medical device sector, emphasizing the integration of innovation across various chains [3]. - The company's journey from a startup in Shanghai to a global leader exemplifies the importance of independent innovation and the necessity of holding core technologies within the company [3].

Group 1 - The core viewpoint of the news is that 联影医疗 (United Imaging Healthcare) has shown significant financial growth in its recent quarterly report, indicating strong performance in the medical imaging equipment sector [2]. - As of February 4, 2026, the stock price of 联影医疗 closed at 129.95 yuan, reflecting a 1.82% increase with a trading volume of 54,100 hands and a total transaction amount of 695 million yuan [1]. - In the recent funding flow data, the net inflow of main funds was 44.32 million yuan, accounting for 6.38% of the total transaction amount, while retail investors experienced a net outflow of 76.86 million yuan, representing 11.06% of the total transaction amount [1]. Group 2 - For the first three quarters of 2025, 联影医疗 reported a main revenue of 8.859 billion yuan, a year-on-year increase of 27.39%, and a net profit attributable to shareholders of 1.12 billion yuan, up 66.91% year-on-year [2]. - The third quarter of 2025 saw a single-quarter main revenue of 2.843 billion yuan, a 75.41% increase year-on-year, and a net profit attributable to shareholders of 122 million yuan, reflecting a 143.8% year-on-year growth [2]. - The company has a debt ratio of 30.08% and a gross profit margin of 47.02%, indicating a solid financial position [2].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [1] Core Insights - The medical device bidding market is expected to maintain high prosperity in 2025, driven by policy and demand resonance, with a projected market size of CNY 193.76 billion, representing a year-on-year growth of 24% [3][11] - The upward trend for medical device companies is clear for 2026, with multiple policies expected to support the continuous development of medical innovation [4][29] - The report emphasizes the importance of high-end product localization and innovation in driving growth for leading domestic companies [33][41] Summary by Sections Bidding Review - The medical device bidding market in 2025 is projected to reach CNY 193.76 billion, with a year-on-year increase of 24%, second only to the peak in 2022 [3][11] - Monthly bidding trends show sustained high levels, with procurement amounts from July to December ranging from CNY 134 billion to CNY 285 billion [3][11] - Key segments such as medical imaging equipment and radiation therapy devices are expected to see significant growth, with year-on-year increases of 35.37% and 36.34% respectively [3][16] 2026 Outlook - The report anticipates a clear upward turning point for medical device companies in 2026, supported by policies aimed at promoting medical innovation and equipment updates [4][29] - The implementation of large-scale equipment updates and consumer replacement policies is expected to further stimulate market demand [4][29] - The report highlights the potential for domestic companies to benefit from high-end product upgrades and the commercialization of brain-computer interface technologies [4][50] Investment Recommendations - The report suggests focusing on leading domestic companies that are enhancing their high-end and intelligent medical device offerings, such as Mindray, United Imaging, and KaiLi Medical [4][33] - It also recommends monitoring companies involved in brain-computer interfaces and domestic robotics, which are expected to see significant growth in the coming years [4][50]

Core Viewpoint - The healthcare sector is experiencing a significant rebound, with the largest healthcare ETF (512170) showing strong performance and attracting substantial capital inflows, indicating renewed investor interest in the sector [1][3][4]. Group 1: ETF Performance - The healthcare ETF (512170) rose over 1.4% after recovering from previous lows, successfully surpassing the 5-day and 60-day moving averages [1]. - The ETF has seen a continuous premium in trading, reflecting active buying interest, with a net inflow of 2.688 billion yuan over the last 12 trading days [3]. Group 2: Earnings Forecasts - As of now, 18 constituent stocks of the healthcare ETF have disclosed their earnings forecasts for 2025, with 11 expected to report profits. Notably, 12 stocks are projected to achieve double-digit growth [4]. - Specific companies like Lepu Medical are forecasting a net profit increase of 224% to 3.86 billion yuan, while other leading CXO firms like Zhaoyan New Drug and Boteng Co. are also expected to see substantial profit growth [4][5]. Group 3: Market Trends - The recovery in the global investment landscape, ongoing domestic support for the innovative drug sector, and a revival in new drug development are contributing to a positive outlook for the CXO industry [4]. - By 2026, structural reforms and improved policy and financing environments are expected to drive the Chinese pharmaceutical industry towards high-quality development [4]. Group 4: ETF Characteristics - The healthcare ETF (512170) is the largest in the market, with a fund size of 27.5 billion yuan, covering over 50% in medical devices and nearly 25% in CXO [6]. - The ETF includes 12 stocks related to AI medical and brain-computer interface concepts, providing a diversified investment opportunity in the healthcare sector [6].

Summary of Key Points Core Viewpoint - The pharmaceutical industry is experiencing a slowdown in revenue growth but is improving in quality and profitability, with a notable increase in innovation and financing activities [2][3]. Group 1: Healthcare Fund and Expenditure - The cumulative income growth of the healthcare insurance fund for 2025 was +3.6%, with urban employee and rural resident contributions growing by +5.5% and +0.8% respectively [5]. - The cumulative expenditure growth of the healthcare insurance fund was +1.7%, with urban employee and rural resident expenditures increasing by +2.8% and +0.4% respectively [6]. - The total expenditure in the healthcare sector for December 2025 was 275.9 billion yuan, reflecting a +12.1% year-on-year increase, with total annual expenditure reaching 2,144.6 billion yuan (+5.7%) [7]. Group 2: Pharmaceutical Manufacturing - The industrial added value of the pharmaceutical manufacturing sector showed a cumulative growth of +2.4% for 2025, with December's growth at +7.0%, surpassing the national industrial growth rate [9]. - The total revenue and profit for the pharmaceutical industry in 2025 were 24,870 billion yuan (-1.7%) and 349 billion yuan (+2.0%) respectively, with a profit margin of 14.0% (+0.5 percentage points) [9]. Group 3: Hospital and Retail Market - The total number of hospital diagnoses in major cities showed improvement in the second half of 2025 compared to the first half, with a slight decrease in discharge numbers [14][19]. - The retail sales of traditional Chinese and Western medicines grew by +1.8% in 2025, indicating a mild recovery trend, although some categories like health products faced significant declines [21]. Group 4: Export and Import Trends - The export of high-value medical devices such as endoscopes and CT machines saw significant growth, with increases of +31.9% and +7.6% respectively in 2025 [27]. - The import of medical devices showed a downward trend, with certain categories like MRI and ultrasound equipment experiencing declines, while CT imports increased by +22.5% [45]. Group 5: Innovation and Financing - A total of 70 new chemical and biological drugs were approved in 2025, a significant increase from 48 in 2024, indicating a robust innovation environment [60]. - The financing amount in the domestic healthcare sector reached 122.8 billion yuan (+46.41%) in 2025, with a notable recovery in IPO activities, which saw a +273% increase in financing amount [65].

证券研究报告 | 行业简评报告 2026 年 02 月 03 日 布局消费反转！ 大消费组二月消费金股 研究部/消费品 % 1m 6m 12m 绝对表现 4.3 4.6 25.0 相对表现 3.1 -8.7 1.7 资料来源：公司数据、招商证券 -10 0 10 20 30 Feb/25 May/25 Sep/25 Jan/26 (%) 消费品 沪深300 相关报告 1、《招商证券 1 月港股消费观察： 外卖反垄断如何影响港股消费股前 景？》2026-01-27 2、《大消费组一月消费金股—双节 消费亮点前瞻》2026-01-06 ❑ 轻纺 杨蕊菁：看好家居板块修复以及倍加洁益生菌业务发展 风险提示：消费下行风险，消费复苏疲软风险、宏观经济变动风险等。 推荐（维持） 行业规模 | | | 占比% | | --- | --- | --- | | 股票家数（只） | 1216 | 23.5 | | 总市值（十亿元） | 17628.3 | 15.6 | | 流通市值（十亿元） | 16321.4 | 15.9 | 行业指数 3、《招商证券 12 月港股消费观察— 1-2 月流动性改善后港股消费买什 么？》2025 ...

Core Viewpoint - The domestic AI-assisted medical technology is advancing, with significant developments in the approval of innovative medical devices and the application of AI in healthcare, indicating a potential for rapid growth in the AI+ healthcare market [1][2]. Group 1: Market Performance - As of February 3, 2026, the CSI Medical and Medical Device Innovation Index (931484) increased by 0.57%, with notable gains from stocks such as Aimeike (+4.07%), Jianfan Bio (+2.36%), and Xinhengcheng (+2.29%) [1]. - The Medical Innovation ETF (516820) also rose by 0.57%, with the latest price reported at 0.36 yuan [1]. Group 2: AI in Healthcare - AI applications in smart healthcare are becoming mature, particularly in medical imaging diagnostics, where AI assists doctors in improving interpretation efficiency [2]. - Recent AI medical products have accelerated their market entry, including the "Cervical Cell Digital Pathology Image Auxiliary Diagnosis Software" approved in January 2026 and the "Yuan Zhi" model from United Imaging, which achieved over 95% accuracy in complex lesion diagnosis [2]. - The combination of technological iteration and policy support is expected to drive rapid growth in the domestic AI+ healthcare market [2]. Group 3: Index Composition - The CSI Medical and Medical Device Innovation Index comprises 30 publicly listed companies with strong profitability, growth potential, and R&D innovation capabilities, reflecting the overall performance of profitable and growth-oriented medical and medical device companies [2]. - As of January 30, 2026, the top ten weighted stocks in the index include WuXi AppTec, Mindray Medical, and Hengrui Medicine, collectively accounting for 63.9% of the index [2].

转自：上观新闻 报告显示，今年上海将推进老旧住宅加装、更新电梯，强化房屋全生命周期安全管理。加强党建引领物 业治理，提升物业服务标准化、专业化水平。加快构建房地产发展新模式，推进"好房子"建设，推动房 地产高质量发展。 报告表示，今年要深化五个新城建设，大力推进新城产业细分赛道发展，提升联影小镇、东方美谷等特 色园区能级，加快松江大学城科创源建设，导入新一批重大产业项目和功能性平台，拓展区区结对合作 深度，建成中山医院国家医学中心青浦院区等公共服务设施。 报告显示，今年要深入实施城市更新行动。推动城中村改造提速扩容增效，全面启动整体改造项目，全 力做好村居民征收安置。完成20万平方米旧住房成套改造。 上海市第十六届人大四次会议2月3日上午在世博中心开幕。上海市市长龚正作《政府工作报告》。 ...